Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

SAN DIEGO, May 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

In this Phase 1b study, 28 stage IV pancreatic ductal adenocarcinoma patients were treated with PEGPH20 in combination with gemcitabine. The overall response rate (CR+PR) was 42 percent* (n=24) as assessed by independent review at therapeutic dose levels of PEGPH20 (1.6 and 3.0 µg/kg). Treatment was generally well tolerated and the adverse event profile was consistent with those seen in previous studies of PEGPH20 as a single agent and as previously reported for gemcitabine alone. There was no evidence of new observed toxicity. Detailed clinical data, including CA 19-9 and pharmacodynamic results will be presented at the meeting.

Emerging data show that most pancreatic cancers surround themselves with a protective hyaluronan-rich matrix, which makes the disease difficult to treat and is itself an indicator of poor prognosis. PEGPH20 depletes this matrix component from the tumor and rapidly changes the tumor microenvironment and metabolism, which may render it more vulnerable to therapy as well as inhibit tumor growth.

"Data from this single arm Phase 1b study clearly reinforce the hypothesis of treating pancreatic cancer with PEGPH20 in conjunction with chemotherapeutic agents," said Joy Zhu , M.D., Ph.D., Vice President, Oncology Clinical Development,
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 27, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... immune therapies for cancer, announced today that Dr. ... Company, will be making an Industry Expert Theater Presentation ... Chicago on Saturday, May 30, 2015, from ... Theater in McCormick Place. Dr. Bosch will ...
(Date:5/27/2015)... May 27, 2015 The Medical Innovation ... impact of regulation on medical innovation, has been developed ... of Fairleigh Dickinson University’s ( FDU ) Rothman ... Alert pertains to new FDA (Food & Drug ... accelerating the approval of certain medical devices. , ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Innovacyn, ... solutions in the human and animal health industries, ... Vetericyn® Future Innovators of Agriculture College Scholarship Award. ... senior who exhibits a passionate commitment to the ... , This year’s winners, Alexis Pedrow from Anderson ...
(Date:5/26/2015)... 26, 2015  Alere Inc. (NYSE: ALR ) (the ... to timely file its Quarterly Report on Form 10-Q for ... it has received a notice from the New York Stock ... with the NYSE,s continued listing requirements under the timely filing ... Manual. The reason for the delay relates ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... Supply Chain Circassia to Develop Dopexamine as Part of ... ... OXFORD, England, October 8 Circassia Ltd, a specialty,biopharmaceutical ... today that it has acquired the US, Canadian and Japanese,development ...
... by allowing for the rapid ... of molecules using a single reaction, ST. LOUIS, ... that it has signed an exclusive licensing,agreement with the ... quantities of powerful new boronic acid,surrogates for use in ...
... for Landmark ApoA-I Trial, TSX Exchange Symbol: ... Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased to ... RVX-208 Phase 2b clinical trial,assessing atherosclerosis by IVUS ... Syndrome patients expected to start in 2009., ...
Cached Biology Technology:Circassia Acquires North American and Japanese Rights to Dopexamine 2Circassia Acquires North American and Japanese Rights to Dopexamine 3Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 2Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement 3International Steering Committee for RVX-208 IVUS Trial Formed 2International Steering Committee for RVX-208 IVUS Trial Formed 3
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... is available in German . During the ... humans, chromosomes are broken and rearranged at many positions. Using ... Klein, professor for genetics at the Max F. Perutz Laboratories ... high resolution. The surprising observations regarding the mechanism of meiosis ...
... part of human history for well over 30,000 years, used ... paint. Now, researchers from the Perelman School of Medicine ... have a new use for the 21st century: protecting healthy ... In a study just published in BMC Cancer , ...
... Total joint replacement surgeries can help relieve joint ... But sometimes, the debris from prosthetic joints leads ... In 2009, a Wayne State University researcher determined ... treat such disintegration. There was one caveat, however: ...
Cached Biology News:The machinery for recombination is part of the chromosome structure 2The machinery for recombination is part of the chromosome structure 3Penn study shows an ancient crop effective in protecting against a 21st century hazard 2Penn study shows an ancient crop effective in protecting against a 21st century hazard 3Wayne State researcher discovers antibiotic useful for localized treatment of bone wear 2
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
cysteine and glycine-rich protein 2,...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
Biology Products: